TD, The first clue about upcoming events comes from a simple head count. LGND was at Oppenehimer "in force". In addition to CEO Robinson, Clinical Reseach VP Steven Reich, and IR's Susan Atkins, LGND brought CFO Paul Maier and CSO Andreas Nigro-Vilar. Maier and Vilar are significant "early indicators" of some major news (Maier on the financial front and Vilar on the science side).
A few of highlights include announcememt of the leptin deal THIS QUARTER, seven INDs in the next 15 months, a second diabetes deal (between AGN and a third party) soon, intense competion between LLY and AGN's partner, exercise (within 2 weeks) of their LLY option to sell a cancer product (maybe 1998, almost certainly in 1999), more advanced clinical data, some major news articles, possibly as early as this weekend, and probably an acquisition.
I think that LGND's contingent is remaining in NY until tomorrow (even though their presentaion was early Tuesday morning).
Sounds like a good time to increase positions or rotatation from high tech into Biotech. Robinson said LGND has the deepest and broadest pipeline in Biotech!, which of course most readers of this board know, but Robinson said it publicly in his talk. |
